Valuation: Becton, Dickinson and Company

Market Cap 50B 43.34B 40.63B 37.05B 69.71B 4,772B 70.83B 478B 187B 2,389B 188B 184B 7,969B P/E 2026 *
37.9x
P/E 2027 * 22.2x
Enterprise Value 65.89B 57.11B 53.54B 48.82B 91.85B 6,288B 93.33B 630B 246B 3,148B 247B 242B 10,501B EV / Sales 2026 *
3.42x
EV / Sales 2027 * 3.24x
Free-Float
73.18%
Yield 2026 *
2.14%
Yield 2027 * 2.17%
1 day+1.04%
1 week+6.60%
Current month+11.67%
1 month+21.14%
3 months+27.48%
6 months+6.53%
Current year-2.90%
1 week 151.8
Extreme 151.8
160.75
1 month 131.3
Extreme 131.3
160.75
Current year 121
Extreme 121
179
1 year 121
Extreme 121
179
3 years 121
Extreme 121
261
5 years 121
Extreme 121
265
10 years 121
Extreme 121
265
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
+1.05%+6.60% - - 50B
-0.28%+2.37%-14.59%+4.17% 192B
-0.11%+5.50%-2.44%+9.00% 116B
-0.13%-3.67%+7.57%+66.86% 59.95B
+2.11%+2.55%+34.34%+62.10% 54.64B
-0.70%+2.91%-7.01%-35.53% 50B
-0.29%+8.91%+13.08%-21.89% 34.26B
+0.86%+3.29% - - 31.15B
-1.38%-0.21%+41.28%-13.01% 24.79B
+0.85%+14.53%-3.89%+20.23% 24.07B
Average +0.19%+4.23%+8.54%+11.49% 65.22B
Weighted average by Cap. +0.09%+4.27%+0.49%+12.39%

Financials

2026 *2027 *
Net sales 19.29B 16.72B 15.67B 14.29B 26.89B 1,841B 27.32B 185B 72.06B 922B 72.42B 70.86B 3,074B 19.73B 17.11B 16.03B 14.62B 27.51B 1,883B 27.95B 189B 73.71B 943B 74.09B 72.48B 3,145B
Net income 1.36B 1.18B 1.11B 1.01B 1.9B 130B 1.93B 13.03B 5.09B 65.08B 5.11B 5B 217B 2.16B 1.87B 1.75B 1.6B 3.01B 206B 3.06B 20.64B 8.06B 103B 8.1B 7.92B 344B
Net Debt 15.88B 13.77B 12.91B 11.77B 22.14B 1,516B 22.5B 152B 59.33B 759B 59.64B 58.35B 2,532B 13.95B 12.09B 11.34B 10.34B 19.45B 1,332B 19.76B 133B 52.11B 667B 52.38B 51.24B 2,223B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
72,000
Date Price Change Volume
26-08-13 160.75 +2.72% 138
26-08-12 €156.50 +1.03% 0
26-08-11 €154.90 +2.04% 27
26-08-10 €151.80 -1.56% 27
26-08-07 €154.20 +2.25% 305
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
183.58USD
Average target price
194.45USD
Spread / Average Target
+5.92%

Quarterly revenue - Rate of surprise